[Abstract Title]. - Society for Neuroscience

contrast, pramipexole and pergolide had a longer duration of activity (≥360 mins) but evoked
only mild-moderate peak AIMs.
In unprimed animals (group 2) daily administration of LD/B and apomorphine induced
maximum peak AIMs scores, ropinirole produced moderately high AIMs (score=3), while
chronic treatment with pergolide expressed mild peak AIMs (score=1-2). Pramipexole induced
only mild orolingual AIMs (score=1).
These data show that in animals primed to express AIMs, LD/B and short acting DRAs express
severe AIMs but long acting DRAs produce only mild to moderate AIMS. In non primed rats
chronic treatment results in the expression of AIMs such that short acting DRAs evoke moderate
to severe AIMs, whereas long acting DRAs show mild or no AIMs. These data confirm the
hypothesis that continuous dopaminergic stimulation with DRAs induces the expression of mild
AIMs compared to the severe AIMs seen with pulsatile dopaminergic stimulation.
Disclosures: M. Papathanou, None; A. McCreary, None; S. Rose, None; P. Jenner, None.
Poster
247. Parkinson's Disease Interventions: Animal and Clinical Models
Time: Sunday, November 16, 2008, 1:00 pm - 5:00 pm
Program#/Poster#: 247.25/T8
Topic: C.02.d. Therapies
Support: Solvay Pharmaceuticals Research Laboratories
Title: Investigation into the chronic effect of pardoprunox (SLV308) treatment upon L-DOPAinduced
dyskinesia in MPTP-treated common marmosets
Authors: *K. STOCKWELL 1,2 , M. J. JACKSON 1,2 , K. TAYARANI-BINAZIR 1,2 , S. ROSE 1,2 ,
A. C. MCCREARY 3 , P. G. JENNER 1,2 ;
1 NDRG, King's Col. London, London, United Kingdom; 2 Proximagen Ltd, London, United
Kingdom; 3 Solvay Pharmaceuticals Res. Labs., Weesp, Netherlands
Abstract: Introduction: Chronic treatment with levodopa (LD) in Parkinson‟s disease (PD)
induces motor complications, notably dyskinesia. Dyskinesia may also be induced to a lesser
extent by full dopamine agonists. When administered with LD, however, severe dyskinesia are
expressed. Whether this is also true for the partial dopamine (DA) agonist pardoprunox is not
known and forms the aim of this study in the MPTP-treated marmoset model of PD.
Methods: MPTP-treated marmosets were primed with LD (12.5 mg/kg) and were maintained on
LD, 3-10 mg/kg, po (+ carbidopa (CD), 12.5 mg/kg, po) such that they had comparable levels of
locomotor activity, motor disability and dyskinesia. Group 1 was treated with LD/CD alone (3-